Rimma Driscoll
Known title: Executive Vice PresidentCIK: 0001952575
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Transaction History
| DXCM | ▲ Buy | Grant | 5,605 | $0 | 5/28/2026 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 179 | $23K | 2/19/2026 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 454 | — | 2/19/2026 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 192 | — | 2/8/2026 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 77 | $10K | 2/8/2026 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 222 | — | 2/6/2026 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 89 | $11K | 2/6/2026 | View on chart |
| DXCM | ▲ Buy | Grant | 5,074 | $0 | 5/8/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 190 | — | 2/8/2025 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 76 | $13K | 2/8/2025 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 102 | $17K | 2/8/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 254 | — | 2/8/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 219 | — | 2/6/2025 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 88 | $15K | 2/6/2025 | View on chart |
| DXCM | ▲ Buy | Grant | 2,632 | $0 | 5/22/2024 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 99 | $20K | 2/10/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 436 | — | 2/10/2024 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 171 | $34K | 2/10/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 290 | — | 2/10/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 187 | — | 2/8/2024 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 75 | $15K | 2/8/2024 | View on chart |
| DXCM | ▲ Buy | Grant | 4,008 | $0 | 8/24/2023 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 120 | $19K | 2/11/2023 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 147 | $23K | 2/11/2023 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 300 | — | 2/11/2023 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 370 | — | 2/11/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM
The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.